Kiniksa Presents Rilonacept Final Phase 2 Clinical Data at the American Heart Association Scientific Sessions 2019

NEXT STORY
BridgeBio and Eidos Present Data from Phase 2 Open Label Extension Suggesting Long-term Tolerability of AG10 and Stabilization of Transthyretin Amyloid Cardiomyopathy Disease Measures
PREV STORY
Colchicine significantly reduces the risk of first and total ischemic cardiovascular events by 23% and 34% respectively in addition to standard of care in patients with a recent myocardial infarction (MI)
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

First Community Bankshares, Inc. Announces Appointment of Director

author_avatar
NASDAQ Market News

Merit Medical Systems to Announce Fourth Quarter and Year End 2020 Results on February 24, 2021

author_avatar
NASDAQ Market News

The University of Texas Health Science Center at Houston joins Biomerica’s InFoods® Irritable Bowel Syndrome (“IBS”) Diagnostic-Guided Therapy (“DGT”) clinical trial

author_avatar
NASDAQ Market News